Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)
This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.
This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Xuesong Bai, Dr.
- Telefonní číslo: 86 18810032664
- E-mail: bxsben@163.com
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
- Age between 18-80 years, both male and female;
- FMA-UE score of 20-50 (inclusive);
- Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
- Right or left upper limb weakness;
- Active flexion/extension of the wrist or fingers;
- Informed consent signed by the patient or a family member.
Exclusion Criteria:
- History of hemorrhagic stroke;
- Persistent dysphagia or choking/coughing while eating or drinking;
- Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
- Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
- Severe or more severe depression (Beck Depression Inventory >29);
- Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
- Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
- Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
- Pregnancy, planned pregnancy, or breastfeeding during the study period;
- Severe upper limb spasticity (modified Ashworth ≥3);
- Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
- Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Active VNS group
After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation. |
After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization. |
|
Falešný srovnávač: Control VNS group
After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation. |
After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
Časové okno: At the end of 6 weeks of hospital treatment.
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
At the end of 6 weeks of hospital treatment.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
Časové okno: 90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
|
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
Časové okno: 90 days
|
The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function. |
90 days
|
|
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
Časové okno: 90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
Časové okno: 90 days
|
The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning. |
90 days
|
|
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
Časové okno: 90 days
|
The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life. |
90 days
|
|
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
Časové okno: 90 days
|
The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life. |
90 days
|
|
Change from baseline in Motor Activity Log (MAL) score at 90 days
Časové okno: 90 days
|
Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity. |
90 days
|
|
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
Časové okno: 90 days
|
The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome. |
90 days
|
|
Adverse events: adverse events occurring during the study period (including the surgical procedure);
Časové okno: From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
|
|
Device complications: any unexpected adverse reactions of the device
Časové okno: From device implantation through the Day 90 follow-up visit.
|
From device implantation through the Day 90 follow-up visit.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- VNS-EARLY
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .